2020年9月
Resumption of anti-programmed cell death 1 monotherapy for severe immune-related adverse events experienced patient with renal cell carcinoma.
IJU case reports
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 3
- 号
- 5
- 開始ページ
- 176
- 終了ページ
- 179
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1002/iju5.12173
Introduction: Combined anti-cytotoxic-T-lymphocyte antigen 4 and programmed cell death 1 blockade induced high rates of immune-related adverse events in patients with renal cell carcinoma. However, the safety of reinitiating anti-programmed cell death 1 monotherapy for patients who discontinued combination therapy due to immune-related adverse events is largely unknown. Case presentation: We report the case of 74-year-old man who received combination therapy with anti-cytotoxic-T-lymphocyte antigen 4 and programmed cell death 1 inhibitors for advanced renal cell carcinoma. After three cycles of combination therapy, he complained severe immune-related adverse events including grade 3 nausea and anorexia, and grade 3 diarrhea, leading to discontinuation of the therapy. He started readministration of anti-programmed cell death 1 monotherapy at 41 weeks after discontinuation due to the new lung metastatic lesion. Importantly, he experienced only grade 1 diarrhea, which can be controlled with prednisolone. Conclusion: The readministration of anti-programmed cell death 1 monotherapy with close monitoring can be an acceptable treatment even after discontinuation of combination therapy.
- リンク情報
- ID情報
-
- DOI : 10.1002/iju5.12173
- PubMed ID : 32914066
- PubMed Central 記事ID : PMC7469840